TY  - JOUR
AU  - Ramadhan, Roy Novri
AU  - Zahra, Sophia
AU  - Rampengan, Derren DCH
AU  - Reviano, Aloysius Denzel Joshua
AU  - Yasin, Muhammad Nabhan
AU  - Jayanthi, Ruthvika
AU  - Raditya, Adrian Faza
AU  - Saputra, Ketut Wahyu Adi
AU  - Ega, Arya
AU  - Ariyanto, Melissa Valentina
AU  - Empitu, Maulana Antiyan
AU  - da Silva , Hendriketa 
AU  - Kadariswantiningsih, Ika N.
TI  - Efficacy and safety of novel beta-lactam/beta-lactamase inhibitor combinations in multidrug-resistant gram-negative bacterial infections: A systematic review and meta-analysis
PY  - %2026/%08/%07
Y2  - %2026/%08/%27
JF  - Acta Biomedica Atenei Parmensis
JA  - Acta Biomed
VL  - 97
IS  - 4
SE  - REVIEWS
DO  - 10.23750/abm.2026.18826
UR  - https://doi.org/10.23750/abm.2026.18826
SP  - 18826
AB  - Background and aim: Multidrug-resistant Gram-negative bacterial infections (MDR-GNB) pose a significant global health challenge, limiting the effectivity of standard antibiotics treatment and contributing to increased morbidity and mortality. Beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations have emerged as promising alternatives to standard antibiotic therapy. This systematic review and meta-analysis aim to evaluate the efficacy and safety of BL/BLI combinations in MDR-GNB infections.Methods: A comprehensive literature search was conducted, including clinical trials comparing BL/BLI combinations with standard antibiotic therapy or placebo. Primary outcomes included clinical cure rates (CCR), microbiological eradication, mortality, adverse events, and survival rates. The risk of bias was assessed using the Revised Tool for Risk of Bias in Randomized Trials (RoB 2.0). Meta-analysis was performed using Review Manager 5.4, and heterogeneity was quantified using the I² statistic.Results: Seventeen studies assessed CCR, demonstrating a significant advantage for BL/BLI combinations (Odds ratio (OR) 2.43 (95% CI 1.95–3.03) ). Thirteen studies reported microbiological eradication, favoring the intervention group (OR 2.45(1.42–4.24)). Twenty studies analyzed mortality, revealing a lower risk in the intervention group (OR 0.44(0.31–0.64)). Eight studies examined adverse events, indicating a lower incidence in the BL/BLI group (OR 0.600.40–0.91)). Three studies evaluated survival rates, showing a significant benefit with BL/BLI combinations (OR 2.02(1.10–3.71)).Conclusions: BL/BLI combinations in MDR-GNB infections significantly improved clinical cure rates, microbiological eradication, and survival. It also reduced mortality and adverse events, highlighting th superiority compared to standard therapy in MDR-GNB
ER  -